PD-1/PD-L1在肿瘤中的机制研究及其在甲状腺癌中的诊治价值

摘要/Abstract

摘要：

程序性死亡受体1(PD-1)和程序性死亡受体配体1(PD-L1)参与免疫检查点调节,与肿瘤的发生和发展密切相关。在甲状腺癌中,PD-L1的表达及PD-1阳性T细胞的增多可能预示着更高的侵袭性与更大的复发风险。抗PD-1/PD-L1治疗在许多肿瘤中已有显著疗效,但在甲状腺癌方面的疗效还比较局限,需要寻找能够更好预测疗效的生物标志物。进一步了解PD-1/PD-L1的作用机制及其在甲状腺癌中的诊治价值以及与其疗效相关的生物标志物,可为甲状腺癌患者提供新的治疗方法与思路。

关键词:甲状腺肿瘤,免疫疗法,PD-1/PD-L1

Abstract:

Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are involved in the regulation of immune checkpoints and are closely related to the occurrence and development of tumors. In thyroid cancer, an increase in PD-L1 expression and an increase in PD-1 positive T cells may be predictive of higher invasiveness and a greater risk of recurrence. Anti-PD-1/PD-L1 therapy has had significant effects in many tumors, but the efficacy in thyroid cancer is still relatively limited, which also requires finding biomarkers those can better predict the efficacy. Further understanding of the mechanism of PD-1/PD-L1, the current research status in thyroid cancer, and biomarkers related to its efficacy may provide new treatment methods and ideas for patients with thyroid cancer.

Key words:Thyroid neoplasms,Immunotherapy,PD-1/PD-L1

张李卓, 钱杨洋, 郑国湾, 葛明华. PD-1/PD-L1在肿瘤中的机制研究及其在甲状腺癌中的诊治价值[J]. 国际肿瘤学杂志, 2020, 47(1): 39-42.

Zhang Lizhuo, Qian Yangyang, Zheng Guowan, Ge Minghua. Mechanism study of PD-1/PD-L1 in tumor and its value of diagnosis and treatment of thyroid cancer[J]. Journal of International Oncology, 2020, 47(1): 39-42.

参考文献34

[1]	Siegel RL, Fedewa SA, Miller KD , et al. Cancer statistics for Hispanics/Latinos, 2015[J]. CA Cancer J Clin, 2015,65(6):457-480. DOI: 10.3322/caac.21314.
[2]	Schlumberger M, Tahara M, Wirth LJ , et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015,372(7):621-630. DOI: 10.1056/NEJMoa1406470.
[3]	Wu X, Gu Z, Chen Y , et al. Application of PD-1 blockade in cancer immunotherapy[J]. Comput Struct Biotechnol J, 2019,17:661-674. DOI: 10.1016/j.csbj.2019.03.006.
[4]	Chowdhury S, Veyhl J, Jessa F , et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants[J]. Oncotarget, 2016,7(22):32318-32328. DOI: 10.18632/oncotarget.8698.
[5]	He J, Hu Y, Hu M , et al. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer[J]. Sci Rep, 2015,5:13110. DOI: 10.1038/srep13110.
[6]	Ahn S, Kim TH, Kim SW , et al. Comprehensive screening for PD-L1 expression in thyroid cancer[J]. Endocr Relat Cancer, 2017,24(2):97-106. DOI: 10.1530/ERC-16-0421.
[7]	Spranger S, Gajewski TF . Impact of oncogenic pathways on evasion of antitumour immune responses[J]. Nat Rev Cancer, 2018,18(3):139-147. DOI: 10.1038/nrc.2017.117.
[8]	Huang Y, Ma C, Zhang Q , et al. CD4⁺and CD8⁺T cells have opposing roles in breast cancer progression and outcome [J]. Oncotarget, 2015,6(19):17462-17478. DOI: 10.18632/oncotarget.3958.
[9]	Ohaegbulam KC, Assal A, Lazar-Molnar E , et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J]. Trends Mol Med, 2015,21(1):24-33. DOI: 10.1016/j.molmed.2014.10.009.
[10]	Wei SC, Levine JH, Cogdill AP , et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade[J]. Cell, 2017, 170(6): 1120-1133.e17. DOI: 10.1016/j.cell.2017.07.024.
[11]	Sanborn RE, Pishvain MJ, Callahan MK , et al. Phase Ⅰ results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events[J]. Cancer Res, 2016,76(14):7614. DOI: 10.1158/1538-7445.AM2016-CT023.
[12]	Hsieh AM, Polyakova O, Fu G , et al. Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions[J]. Oncotarget, 2018,9(28):19767-19782. DOI: 10.18632/oncotarget.24833.
[13]	Fu G, Polyakova O, Macmillan C , et al. Programmed death-ligand 1 expression distinguishes invasive encapsulated follicular variant of papillary thyroid carcinoma from noninvasive follicular thyroid neoplasm with papillary-like nuclear features[J]. EBioMedicine, 2017,18:50-55. DOI: 10.1016/j.ebiom.2017.03.031.
[14]	Bastman JJ, Serracino HS, Zhu Y , et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer[J]. J Clin Endocrinol Metab, 2016,101(7):2863-2873. DOI: 10.1210/jc.2015-4227.
[15]	Antonelli A, Ferrari SM, Fallahi P . Current and future immunotherapies for thyroid cancer[J]. Expert Rev Anticancer Ther, 2018,18(2):149-159. DOI: 10.1080/14737140.2018.1417845.
[16]	Mehnert JM, Varga A, Brose MS , et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer[J]. BMC Cancer, 2019,19(1):196. DOI: 10.1186/s12885-019-5380-3.
[17]	Prasongsook N, Kumar A, Chintakuntlawar AV , et al. Survival in response to multimodal therapy in anaplastic thyroid cancer[J]. J Clin Endocrinol Metab, 2017,102(12):4506-4514. DOI: 10.1210/jc.2017-01180.
[18]	Cantara S, Bertelli E, Occhini R , et al. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer[J]. Endocrine, 2019,64(1):122-129. DOI: 10.1007/s12020-019-01865-5.
[19]	Gunda V, Gigliotti B, Ndishabandi D , et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer[J]. Br J Cancer, 2018,119(10):1223-1232. DOI: 10.1038/s41416-018-0296-2.
[20]	Gunda V, Gigliotti B, Ashry T , et al. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer[J]. Int J Cancer, 2019,144(9):2266-2278. DOI: 10.1002/ijc.32041.
[21]	Kollipara R, Schneider B, Radovich M , et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer[J]. Oncologist, 2017,22(10):1149-1151. DOI: 10.1634/theoncologist.2017-0096.
[22]	Iyer PC, Dadu R, Gule-Monroe M , et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma[J]. J Immunother Cancer, 2018,6(1):68. DOI: 10.1186/s40425-018-0378-y.
[23]	Chintakuntlawar AV, Yin J, Foote RL , et al. A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer[J]. Thyroid, 2019,29(1):1615-1622. DOI: 10.1089/thy.2019.0086.
[24]	Elisei R, Pinchera A . Advances in the follow-up of differentiated or medullary thyroid cancer[J]. Nat Rev Endocrinol, 2012,8(8):466-475. DOI: 10.1038/nrendo.2012.38.
[25]	Yamaga LYI, Cunha ML, Campos Neto GC , et al.⁶⁸Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with¹¹¹In-octreotide SPECT/CT and conventional imaging [J]. Eur J Nucl Med Mol Imaging, 2017,44(10):1695-1701. DOI: 10.1007/s00259-017-3701-9.
[26]	Schlumberger M, Elisei R, Müller S , et al. Overall survival analysis of EXAM, a phase Ⅲ trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma[J]. Ann Oncol, 2017,28(11):2813-2819. DOI: 10.1093/annonc/mdx479.
[27]	Shi X, Yu PC, Lei BW , et al. Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical recurrence/persistent disease in medullary thyroid carcinoma[J]. Thyroid, 2019,29(9):1269-1278. DOI: 10.1089/thy.2019.0079.
[28]	Kang J, Demaria S, Formenti S . Current clinical trials testing the combination of immunotherapy with radiotherapy[J]. J Immunother Cancer, 2016,4:51. DOI: 10.1186/s40425-016-0156-7.
[29]	Hellmann MD, Nathanson T, Rizvi H , et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer[J]. Cancer Cell, 2018, 33(5): 843-852.e4. DOI: 10.1016/j.ccell.2018.03.018.
[30]	Sunshine J, Taube JM . PD-1/PD-L1 inhibitors[J]. Curr Opin Pharmacol, 2015,23:32-38. DOI: 10.1016/j.coph.2015.05.011.
[31]	Hellmann MD, Ciuleanu TE, Pluzanski A , et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018,378(22):2093-2104. DOI: 10.1056/NEJMoa1801946.
[32]	Vanderwalde A, Spetzler D, Xiao N , et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients[J]. Cancer Med, 2018,7(3):746-756. DOI: 10.1002/cam4.1372.
[33]	Bagley SJ, Kothari S, Aggarwal C , et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer[J]. Lung Cancer, 2017,106:1-7. DOI: 10.1016/j.lungcan.2017.01.013.
[34]	Kamphorst AO, Pillai RN, Yang S , et al. Proliferation of PD-1⁺CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients [J]. Proc Natl Acad Sci U S A, 2017,114(19):4993-4998. DOI: 10.1073/pnas.1705327114.